Tromsø, Norway, 26th March 2021 – ArcticZymes Technologies ASA (OSE: AZT) announces it has successfully scaled-up the manufacturing of its SAN HQ enzyme
ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme offers gene therapy and vaccine customers a more cost effective and technically superior solution for the removal of contaminating DNA during the manufacturing process of therapeutic viruses.
The Company entered the therapeutic segment with its SAN portfolio in 2016. Since then, it has rapidly grown its customer base and subsequent sales. In 2020 the segment accounted for 41% of total sales revenues and demand continues to grow. As a consequence, there was a need to transition from small-scale fermentation production into significantly larger-scale fermenters so that customers can receive large quantities of enzyme from a single production batch. This successful upscaling achieved greater than a 100-fold increase in fermentation yield and enzyme manufactured from this upscaled process will be commercially available to our customers from early Q2.
The project was partial funded by a national grant received in May 2020 from Innovation Norway. We are grateful to Innovation Norway for supporting the project and recognizing its underlying value.
ArcticZymes Technologies ASA, CEO, Jethro Holter said:
“The upscaling of SAN HQ is core to ensure continuity of supply to our customers as we mutually grow business together.”
For more information, please contact:
|CEO, Jethro Holter
CFO, Børge Sørvoll
|Tel: +47 46 85 91 46
Tel: +47 95 29 01 87